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Abstract: This article proposes and develops novel components of community-oriented 
programs for creating and affording access to safe medication dispensing centers in existing 
retail pharmacies and in permanent or travelling pharmacy clinics that are guarded by assigned or 
off-duty police officers. Pharmacists at these centers would work with police, medical providers, 
social workers, hospital administrators, and other professionals in: planning and overseeing 
the safe storage of controlled substance medications in off-site community safe-deposit boxes; 
strengthening communication and cooperation with the prescribing medical provider; assisting 
the prescribing medical provider in patient monitoring (checking the state prescription registry, 
providing pill counts and urine samples); expanding access to lower-cost, and in some cases, 
abuse-resistant formulations of controlled substance medications; improving transportation 
access for underserved patients and caregivers to obtain prescriptions; and integrating com-
munity agencies and social networks as resources for patient support and monitoring. Novel 
components of two related community-oriented programs, which may be hosted outside of 
safe medication dispensing centers, are also suggested and described: (1) developing medica-
tion purchasing cooperatives (ie, to help patients, families, and health institutions afford the 
costs of medications, including tamper- or abuse-resistant/deterrent drug formulations); and 
(2) expanding the role of inner-city methadone maintenance treatment programs in palliative 
care (ie, to provide additional patient monitoring from a second treatment team focusing on 
narcotics addiction, and potentially, to serve as an untapped source of opioid medication for 
pain that is less subject to abuse, misuse, or diversion).
Keywords: controlled substances, diversion, drug abuse, inner-city, methadone, methadone 
maintenance treatment, pain, palliative care, pharmacy, prescription drugs, rural, safety, 
tamper- and abuse-resistant drugs, TARD, transportation
Converging economic factors and bioethical concerns will increasingly direct the 
options for pain control that will be made available to patients, families, and health 
care institutions, especially in inner-city and rural settings. Health insurers face 
pressures to limit coverage of less cost-effective options for pain-relieving opi-
oids and other medications, at the same time that health institutions, patients, and 
families are restricting the level of out-of-pocket, or nonreimbursed, costs that they 
will bear.1 However, many other costs, difficult to assess in economic terms, must 
also be considered, especially the repercussions from drug abuse and diversion on 
patients, families, physicians, communities, and society. Alarmingly, prescription Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
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drug abuse is now the second leading cause of unintended 
death in the United States.2 Determining which options for 
pain management are humane, affordable, and acceptable 
in any given context requires assessment of: (1) addiction 
and drug diversion not only by patients but by their caregiv-
ers, family, and social contacts; (2) personal safety of the 
patient, caregiver, and family members from drug dealers; 
and (3) perceptions of stigma by the patient, caregiver, 
and family.
In inner-city and rural areas, health providers often 
find it difficult to obtain medications, face higher costs 
for medications, and struggle to ensure their safe delivery. 
Restrictions by physicians in prescribing medication,3,4 
and by pharmacists in stocking them,5,6 exist where there 
are serious concerns over illegal drug trafficking and drug-
related crime. The United States Drug Enforcement Agency 
(DEA) prosecutes physicians when patients divert drugs that 
were prescribed to relieve pain,7 which reinforces physi-
cian reluctance to prescribe pain medications in sufficient 
quantities when there may be any possibility for diversion 
or abuse.3,4 On the other hand, it may be anticipated that 
patients and caregivers could increasingly come to fear for 
their safety and therefore avoid well stocked pharmacies 
in communities, regardless of their geography, that have 
experienced increased incidents of hold-ups, shootings, or 
other violent crime.8
Retail pharmacies and pharmacy 
clinics in the community: innovations 
for safety and prevention
In response to evidence that inner-city pharmacies do not 
stock opioids due to the potential for assault, theft, and 
vandalism5,6 – and as options for any geographic location 
in which crime or shootings at retail pharmacies may drive 
away customers8 – this article presents a vision of alternative 
pharmacy options, that involve improving the safety of retail 
pharmacies and pharmacy clinics in the community. These 
alternative options merit serious consideration for research 
and program development.
Community pharmacists in inner-city and rural areas may 
be more willing to dispense opioid medications and other 
controlled substances as long as (1) an on-duty police officer 
can be assigned or an off-duty police officer hired to provide 
on-site protection; and (2) supplies of opioid medications 
can be safely stored offsite, with the police officer trained 
to obtain and transport, on a periodic basis, the types and 
amounts that the pharmacist anticipates will be needed. In 
this option, community pharmacists would dispense these 
medications at a retail pharmacy, or at a permanent or travel-
ing pharmacy clinic held at other community locations, such 
as church basements, fraternal organizations (eg, Veterans of 
Foreign Wars or Masonry halls), town halls, hospitals and 
outpatient hospital clinics, nursing homes and assisted living 
sites, and farm supply stores. The presence of a police officer 
in a retail pharmacy, or at common community locations that 
host a pharmacy clinic, may avoid much of the stigma that 
patients and caregivers may be likely to experience com-
pared, for instance, to locating a retail or clinic pharmacy 
at a local police, sheriff, or state police station, although 
research evidence is needed to confirm this reaction. For 
this innovative type of program to work, several features 
need to be adopted.
First, safety concerns may mean that opioid medications 
and other controlled substances should be delivered to the 
local police or sheriff station, where they would be handled, 
labeled, and stored by the pharmacist. (These medications 
may include lower-priced, mail-order medications from 
Internet pharmacies purchased as part of a community health 
consortium, as discussed below.) The pharmacist and police 
officer, or the police officer alone, would then transport 
medications and store them in safe deposit boxes obtained 
for this purpose that are located in restricted access areas at 
police/sheriff stations, banks, and/or post offices. (Safe deposit 
boxes are located not only at banks, but at post offices in 
some communities,9 which would appear to be an option for 
consideration in others, along with locating safe deposit boxes 
in police stations). These locations should be dispersed across 
different geographic regions of the inner-city, rural area, or 
other type of community. The pharmacist must also train the 
police officer in the proper procedures for identifying and han-
dling these medications and transporting them from the safe 
deposit boxes to the retail pharmacy or pharmacy clinic.
Second, these safe deposit boxes should only be acces-
sible by the pharmacist and the police officer. The phar-
macist, perhaps accompanied by the police officer, would 
stock safe deposit boxes with medication. (Subsequently, 
the police officer would travel alone to select periodi-
cally only the needed types and quantities of medication 
from these safe deposit boxes for delivery to the com-
munity pharmacy or pharmacy clinic.) A search of the 
literature and the Internet by the author did not reveal state 
or federal laws that prohibit legally obtained controlled 
substances from being stored in safe deposit boxes. More-
over, legal drugs are typically not among the restrictions 
listed on agreement forms for use of safe deposit boxes 
at banks.10,11 (Banks are also free to tailor their agreement   Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
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forms to these special circumstances in order to better meet 
the needs of the bank and the institutions represented by the 
pharmacist and police officer.) In addition, new biometric 
instant recognition technologies, such as three-dimensional 
reading of a hand’s size and shape, provide additional safety 
for preventing robberies,12 although traditional safe deposit 
boxes (ie, accessed using a key after an attendant unlocks 
the room with a separate key) may be considered sufficient, 
especially in smaller communities.
Third, the police officer should arrive with the appropri-
ate medications, and in the required quantities, sufficiently 
in advance of when the pharmacist begins prescribes medi-
cations during scheduled appointments with patients or their 
caregivers. (Limited quantities of these medications should be 
dispensed during each visit by a patient or their caregiver in 
order to reduce the chances that they will become targets for 
assault and theft of their medication, and to reduce the chances 
that they will divert or abuse the medication. As discussed 
later in this article, pill counts of remaining medication could 
be required before renewing a prescription, and increases in 
prescription quantities over time could be approved when pill 
counts do not suggest problems.)   Scheduling appointments 
during restricted hours and days that are set aside for prescrib-
ing opioids and other controlled substances should improve 
cost feasibility since the police officer will only provide on-site 
protection during limited hours.
Additional security features already used by some phar-
macies include a locked entrance with an outdoor buzzer that 
can be viewed by camera, which permits access only to those 
with a scheduled appointment, and a sign on the outside door 
stating that the pharmacy does not stock opioid pain medica-
tions, such as oxycodone, nor other controlled substances. 
Local ordinances may prohibit loitering near the pharmacy, 
especially when controlled substances are prescribed, and 
in some cases, police officers may obtain restraining orders 
to prevent certain individuals with drug addiction or diver-
sion involvement from approaching the pharmacy.
These program components may be adopted not only by 
retail pharmacies but by pharmacy clinics (including tempo-
rary or rotating clinics) that would likewise improve safety 
of medication dispensing by using assigned (ie, on-duty) or 
hired (ie, off-duty) police officers. Pharmacy clinics operated 
by the local hospital provide an important alternative to the 
retail pharmacy, which may not exist or be feasible to operate, 
especially in rural areas. Additional safety protection may 
result to the extent that community locations for these clinics 
are not selected according to a publicized and predictable 
schedule and to the extent that patients and caregivers with 
scheduled appointments can keep the locations   confidential. 
In rural areas with scattered populations and with vast 
distances that need to be served, the costs of using police 
officers for a pharmacy clinic (which would need to cover 
their traveling times) are likely to be prohibitive. A travelling 
clinic may be more feasible in inner-city areas with good 
transportation options and in semirural regions punctuated 
by areas that are more densely populated.
Funding for prevention from the recent federal health 
care reform legislation, the Affordable Care Act, as well as 
  Medicare, might be tapped since close monitoring for medi-
cation adherence could provide more cost-effective manage-
ment of disease conditions and prevent pain and symptoms 
from becoming out of control due to medication mismanage-
ment or drug diversion. The DEA and local philanthropies 
may be additional sources of potential funding to subsidize 
the costs of assigning a police officer, or hiring one off-duty, 
who would obtain and transport controlled substance medica-
tions from community safe-deposit boxes to either a retail 
pharmacy or a pharmacy clinic, as well as provide on-site 
police protection.  These police officer functions constitute 
two critical program components for safe dispensing of 
medication and prevention of prescription drug abuse.
Cost savings from online purchasing of wholesale medi-
cations in bulk as a mail-order from a consortium of health 
care institutions could also provide funding and operational 
advantages. The consortium could involve pharmacies 
located in the community and within hospitals, and that 
serve nursing homes, visiting nurse services, and hospices. 
Some cash-strapped hospitals and visiting nurse associations 
in rural areas have organized into consortiums that order 
medications online from large, wholesale medicine-ordering 
cooperatives that bypass the middle retail pharmacy.13 
However, a consortium might include urban, suburban, 
and rural institutions within the same geographic regions.14 
Wholesale, online medicine-ordering cooperatives can ship 
medications directly to home addresses, hospitals and neigh-
borhood pharmacies,13 and other locations. Social workers, 
health providers, and health administrators from rural and 
inner-city hospitals, visiting nurse associations, and pallia-
tive care programs could advocate for this option to reduce 
unreimbursed medication expenditures borne by patients, 
families, and the health institution.14
Transportation issues: innovations in 
service delivery and reimbursement
Some patients and designated caregivers from sprawling 
inner cities and vast rural counties are likely to find it Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
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prohibitive to travel alone, contend with complicated 
public transportation systems, or drive long distances 
to retail pharmacies or pharmacy clinics. In some situa-
tions, a bus, van, or car option could transport residents 
to the retail pharmacy or travelling pharmacy clinic, as 
well as the return trip home. The additional costs to the 
community of this transportation option may be offset to 
some extent by a transportation charge on a sliding scale 
based on patient income, or by a fare in the case of the 
use of preexisting public transportation. A transportation 
option may be more feasible financially to operate in 
inner-city areas, however in semirural regions, it may still 
be worthwhile to assess whether cost savings in averted 
or delayed hospital admissions could justify a car or van 
option. Moreover, these additional transportation costs 
could be argued in many cases to offset the eventual 
inpatient hospital costs that are borne by the community, 
including uncompensated care and the share of Med-
icaid reimbursement financed through local and state 
taxation. Late referrals of individuals with exacerbated 
illness, who present with long-neglected pain and other 
symptoms become more difficult and more expensive to 
control, in contrast to when residents obtain early and 
sustained palliation and control of their symptoms.15,16 
Advocacy with public and private insurers to cover these 
transportation expenses as part of preventive/palliative 
care should be considered since these health insurers ulti-
mately stand to save money – not necessarily over patient 
life spans (since preventive care and symptom palliation 
might cause a patient to live longer) – but over the more 
critical short-term period of the annual fiscal year. To 
health insurers, the annual fiscal year is the bottom-line 
period for assessing net profitability and total revenues 
from annual enrolments in private plans as well as annual 
public reimbursements financed through local, state, and 
federal taxation. Social workers, other clinicians, and staff 
from hospital reimbursement departments could work 
together to advocate for transportation service delivery 
and reimbursement.
Options for round-trip transportation merit consideration 
that would offer the only means of access by individuals from 
underserved groups in the community. The lowest cost trans-
portation option may be based on a predetermined limited 
schedule of operation, a direct route, and express service with 
only a single stop between the retail pharmacy or travelling 
clinic and a specific location in the community. This lowest 
cost approach may make it feasible to take advantage of 
untapped opportunities to reach concentrated populations of 
underserved populations.
For instance, homeless individuals, including those 
who reside at shelters, cannot safely store a prescription 
supply of opioids and other medications and a frequent 
need to migrate may compromise safety in other ways. 
Safety issues are especially salient when a homeless per-
son with a supply of opioid medications stays at a shelter, 
since they may become magnets for assault and violence 
from other residents at these facilities who are actively 
abusing drugs or involved in diversion activities. These 
difficulties may mean that at least some homeless indi-
viduals, and their physicians, would welcome the option 
to obtain and consume medications within the safety of a 
retail or hospital pharmacy or a traveling pharmacy clinic 
guarded by a police officer, as long as they felt reassured 
that the officer would not harass them. Community groups 
could be mobilized to help set up round-trip transportation 
between a local shelter and the pharmacy or pharmacy 
clinic in order to prevent loitering and provide an option 
for temporary lodging after medications are consumed. 
In addition, when a hospital pharmacy has continuous 
hours of operation, a locked box of medications could be 
kept in the dispensing room for a homeless individual to 
travel there in order to consume prescribed medications 
onsite and/or to obtain medications for a short period. It 
is unclear, however, whether tamper- or abuse-resistant 
or deterrent (TARD) medications, discussed next, would 
afford greater safety to homeless individuals so that they 
could obtain a larger supply of medications for a longer 
period.
Drug formulation improvements
Nursing homes are other settings in inner-city and rural 
communities that are vulnerable to medication diversion and 
abuse. Because nursing homes operate without doctors or 
pharmacies on their premises, pain medications are delayed 
due to the mandate by the DEA that pain medications be 
prescribed only after written signatures from physicians are 
faxed to off-site pharmacies.17,18 Pain medication delays are 
especially lengthy for residents with pain exacerbation in the 
middle of the night or who are in transition from the hospital. 
These mandates are designed to lower the potential for drug 
theft and abuse by nursing home staff. New TARD formula-
tions of narcotics are designed to discourage prescription 
drug abuse and diversion.1 Advocacy efforts to gain excep-
tions to this DEA mandate could be more compelling when Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
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they are sought for situations in which TARD formulations 
are used.
However, TARD formulations tend to be more expen-
sive, posing greater financial burden for underinsured and 
lower socioeconomic populations.1,19 It has been suggested 
elsewhere that hospitals, hospices, and nursing homes from 
inner-city, urban, suburban, and rural areas could engage col-
lectively as a consortium to allow online mail-order purchases 
of a wider range of medications, including TARD formula-
tions, at reduced costs to these health facilities and to patients 
and families.14 Cost savings from medications purchased as 
a consortium could be used to (1) offset financial burden by 
patients, families, and health facilities in meeting unreim-
bursed medication expenses; and/or (2) help finance service 
delivery innovations such as a round-trip   transportation 
service or a permanent or travelling safe medication dispens-
ing center within the community. Social workers and health 
providers within the same geographic region could network 
with each other to assess the potential to work towards this 
kind of macrosystem change for their health institutions and 
communities.14
TARD preparations of opioid medications are specially 
formulated to be difficult to melt or crush so that they cannot 
be injected or inhaled.1,19 Other formulations become inacti-
vated when melted or crushed, which releases a second drug 
with significantly greater affinity for the microopioid recep-
tor, thus displacing the opioid from binding to the receptor. 
A methadone/naloxone 50:1 preparation, for instance, was 
developed in Australia to eliminate diversion and injection 
of prescribed methadone.20 An inexpensive and synthetic 
opioid, methadone is likely to be more cost-effective when 
formulated as a TARD preparation than TARD preparations 
based on other opioids, which could result in significant 
savings for health institutions, patients, and families. Other 
TARD options, such as sublingual buprenorphine-naloxone 
tablets or subdermal buphrenorphine implants,21 are based 
on opioids with a better safety profile than methadone, which 
is contraindicated in certain patients due to the potential for 
life-threatening interactions with other medications, treat-
ments, or conditions.
Despite the enhanced safety and affordability that some 
TARD medications could provide, there is no evidence that 
TARD formulations will prevent patients who abuse or divert 
opioid drugs from seeking to manipulate medical personnel 
into prescribing excess amounts, or stronger than necessary, 
drugs.19 Still, TARD formulations may make it more difficult 
for patients, family members, or friends to abuse them and 
less worthwhile to divert them. These advantages may hold 
promise for curtailing thefts of medications by nursing home 
employees and from community pharmacies, which could 
be easily monitored to determine whether medication thefts 
decrease when TARD formulations are used.
Strategically linking palliative 
pharmacotherapy to community 
programs and resources
Methadone maintenance treatment 
programs
The fact that opioid medications for pain are narcotics may 
lead patients and family members to feel stigma, especially 
in inner-city and rural areas that struggle with drug addiction 
and are caught up with efforts to curtail black market drug 
diversion activities. Patients receiving methadone, in particu-
lar, to relieve pain have disclosed perceptions of stigma.22,23 
This stigma relates to the parallel use of methadone at metha-
done maintenance treatment programs (MMTPs) to manage 
craving in those with the disease of addiction; the mention 
of methadone as a medication for pain is often interpreted 
as a message that we are treating an unacknowledged but 
presumed addiction in the patient. Social workers and health 
providers who are aware of those faulty attributions can 
assist patients and families to consider use of methadone for 
pain by raising concerns, acknowledging fears, exploring any 
addiction history, and educating about the use of methadone 
for pain management. Without intervention, it is unclear 
whether stigma will remain sufficiently strong to override the 
use of methadone for chronic pain, especially when patients 
are underinsured for more costly opioid prescriptions or 
neighborhood pharmacies do not stock them.6
Ironically, the very source of this stigma may provide 
another option to TARD preparations for safe and affordable 
methadone to treat pain. In some inner-city areas, MMTPs 
already serve individuals who are addicted to euphoria-
inducing narcotics. These clinics merit serious consideration 
as an untapped source of opioid medication for the pallia-
tive relief of pain that is potentially less subject to diversion 
than other delivery systems for opioid medications. Patients 
with HIV (human immunodeficiency virus)/AIDS (acquired 
immune deficiency syndrome) and already receiving treat-
ment for narcotic addiction at MMTPs have been treated 
successfully with additional methadone in these programs 
to relieve diverse chronic pain syndromes.24 Moreover, it 
should also be considered whether methadone delivered at Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
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an MMTP could provide a safer and more attractive option 
not only for patients in pain with narcotics addictions, but 
for other patients (1) whose physicians would otherwise 
resist prescribing opioids in sufficiently high doses needed 
to relieve pain; and (2) who may not have safe access, or 
financial access, to opioids for use at home, including home-
less populations.25
However, state government regulations often restrict 
MMTPs to treating narcotics addiction (and not pain relief).25 
Barriers to access include daytime hours of operation, and 
automatic daily treatment regimens of 5–7 days of the week, 
which employed patients and family caregivers cannot meet, 
as well as payment mechanisms set up only for Medicaid 
reimbursement (ie, other health insurance or out-of-pocket 
payment cannot be accommodated). Even so, the changing 
makeup of the population with narcotics addictions could 
provide new opportunities for these clinics; for instance, 
there appears to be bipartisan interest in the chronic physi-
cal and mental health problems of veterans returning from 
  Afghanistan and Iraq. Affording veterans with improved 
access to these clinics may reduce stigma and enhance the 
community profiles of these programs, which could build 
momentum to serve more clients with narcotics addictions.
The involvement of two treatment teams in patient 
monitoring and professional consultation is advantageous and 
recommended.4 Even when MMTPs do not deliver additional 
methadone to relieve pain, patients attending these clinics to 
treat narcotics addiction require close coordination by the 
palliative care team (which may be using opioid medication 
to treat pain) and the MMTP treatment team. Drug screenings 
such as urine drug screens, recommended as part of the Utah 
clinical guidelines on prescribing opioids for treating pain,26 
could be performed by each team. Although clinical practice 
recommendations provide maximum doses to reduce the 
risk of overdose and death,22,27–29 physicians may not be well 
versed about how methadone can interact with medications 
and present risks for overdose and death. Thus, only experi-
enced palliative care physicians committed to close patient 
monitoring should prescribe methadone to relieve pain.26
The assistance of a second treatment team at an MMTP 
may be an important factor in determining how closely the 
patient can be monitored. When two treatment teams are 
involved, each team should document a separate patient 
agreement not to abuse narcotics while receiving methadone,4 
which could afford additional legal protection. Nurses and 
social workers from both teams should closely follow patients 
who are modifying their MMTP treatment of narcotics 
addiction to relieve chronic pain as well, in order to detect 
and address barriers to adherence and to overtreatment, 
especially new or worsening side effects that indicate risks 
for arrhythmia and sudden death (eg, see Shaiova et al22). In 
addition to biological or medical contraindications, MMTP 
treatment for pain management may be compromised by 
psychosocial barriers for medication adherence in specific 
populations, as documented in HIV-positive individuals with 
one or more psychiatric diagnoses.30
Pharmacy clinics and retail pharmacies
The criminal justice system and the neighborhood and 
regional environment, it may be argued, discriminate against 
many patients of lower socioeconomic status by denying them 
adequate access to pain and symptom relief. In particular, 
many physicians do not prescribe opioids, or in sufficient 
quantities, when there is any possibility of narcotics abuse or 
diversion because they fear being prosecuted by the DEA.3,4 
Furthermore, inner-city pharmacies typically do not stock 
opioid medications due to the likelihood of assault, theft, and 
vandalism,5,6 and pharmacies in rural areas are rare. Given 
this austere reality, it is quite understandable that palliative 
care clinicians are often wary about innovations that seek 
to link, and limit, palliative care to contexts in which health 
providers are involved directly in efforts to control narcotics 
abuse and diversion.
However, in place of directly linking program components 
that discourage prescription drug abuse to outpatient pallia-
tive care (or to primary care services), health providers may 
express support for incorporating these types of innovative 
program linkages into the operations of retail pharmacies 
and pharmacy clinics. Professional self-interest may be an 
important factor. By associating with these innovative pro-
grams, health providers may feel more secure in the event of 
a DEA, police, or malpractice investigation. Pharmacists, in 
turn, may be receptive to adopt these program changes since 
they may become associated with perceptions of improved 
safety, which is important for attracting and retaining good 
pharmacy customers.   Furthermore, pharmacists are increas-
ingly informants about patients and their prescription drug 
use activity in state prescription drug monitoring program 
registries that operate in 38 states.31 (These state registries are 
tracked by local, state, and federal law enforcement agencies; 
some physicians also monitor their state registry to assess 
whether their patients are also seeking pain medications from 
other physicians or locations in the state in order to detect 
situations of potential prescription drug abuse or diversion.31 
Pharmacists, however, can alert all physicians when their 
referrals appear on the registry.) Closely tied to pharmacist Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
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participation in state prescription monitoring programs, 
a pharmacist-directed program also provides a valuable 
opportunity for them to offer public health education to pre-
vent prescription drug abuse. For instance, pharmacists can 
instruct patients and caregivers not to keep highly addictive 
and potentially lethal medications in the bathroom medicine 
cabinet or other open areas where they can be ingested or 
stolen by children, family members, or visitors.
How might innovative programs in pharmacy clinics 
and retail pharmacies actually be linked to the more limited 
efforts that we may reasonably expect of health providers 
from outpatient palliative care or primary care services in 
order to prevent and discourage prescription drug abuse? 
Community health providers who do not provide their own 
follow-up appointments to monitor patient medications, could 
be asked to do so or to require – as a condition of receiving a 
prescription for a controlled substance medication and any 
future refills – that their patients (or primary   caregivers) 
attend periodic appointments at a pharmacy clinic, retail 
pharmacy, or other supportive community agency in order 
to provide pill counts (typically based on a labor-saving pill-
counting machine). (These pharmacists and other providers 
would be notified in advance of any newly referred patients.) 
This condition for receiving a prescription from a commu-
nity health provider would apply even to patients receiving 
medications delivered to their homes from online pharmacies. 
Bulk purchasing of online medications through a commu-
nity health consortium, as discussed earlier, could subsidize 
costs to the pharmacy clinic or retail pharmacy, and patients 
purchasing directly from online pharmacies could still be 
charged a fee to cover the costs for pill counts and patient 
monitoring at the pharmacy clinic or retail pharmacy.
When pill counts are acceptable, appointments for pill 
counting could occur less frequently to minimize inconve-
nience, and a larger number of pills could be dispensed in 
prescription renewals.
If a pill count reveals too many missing pills, the health 
provider would be notified. Should the physician still decide 
to renew the prescription, the pharmacist would dispense a 
smaller quantity of pills and require more frequent pharmacy 
appointments to conduct pill counts and perhaps even to pro-
duce onsite a urine sample for lab analysis (described in the 
next paragraph). In any event, the pharmacist would notify the 
health provider to schedule a follow-up patient appointment 
in order to take a urine sample for lab analysis. (The health 
provider should not announce to the patient or caregiver in 
advance the plan to draw a urine sample in order to increase 
the chances for detecting drug abuse or misuse based on 
excessive or insufficient concentrations of the metabolized 
medication in the urine.) When there is evidence of potential 
abuse or diversion, the pharmacist would refuse to fill future 
prescriptions, and inform local police. In other situations, 
patients or caregivers who are actively abusing or diverting 
the medication may seek to bypass this local monitoring by 
purchasing controlled substances from online “rogue pharma-
cies,” which do not even require a prescription.32 However, 
their failure to attend periodic pharmacy appointments would 
serve as a clue that patients, caregivers, family members, or 
friends could be abusing or diverting medication, and the phar-
macist would notify the physician and perhaps the police.
When patients, their caregivers, or family members 
have past, current, or suspected involvement in drug abuse 
or   diversion, both the health provider and pharmacy clinic 
should require that as part of the agreed plan for pain control, 
the patient will provide periodic urine samples onsite and 
under observation (ie, to prevent fraudulent urine samples; 
patients could be charged a fee). A safe medication dispensing 
center at a retail pharmacy could even perform this pharmacy 
clinic function by requiring a urine sample whenever these 
patients or their caregivers seek to fill a controlled substance 
medication prescription. Ideally, a single nursing assistant 
or aide would oversee the patient as they produce the urine 
sample in a private area; however, monitoring could also be 
carried out by the pharmacist or trained volunteer of the same 
gender as the patient. Either the pharmacist or the police offi-
cer providing clinic protection would deliver urine samples to 
the hospital for analysis, and the results would be reported to 
the health provider and pharmacist. Insufficient or excessive 
concentrations of the metabolized drug in the urine would 
provide a signal of drug abuse, misuse, or diversion by the 
patient, caregiver, family members, or social contacts, which 
may include supplementing pills through “doctor shopping” 
or using “rogue” mail-order pharmacies to obtain controlled 
substance medications without a prescription.
Community agencies and social networks
It is possible, however, that the use of assigned or off-duty 
police at retail pharmacies or pharmacy clinics may discourage 
some patients with active or past involvement in drug abuse 
or diversion, or with criminal records, who have a legitimate 
need for medications to relieve pain or other symptoms. On 
the other hand, it is common, and disturbing, that patients 
who abuse or divert drugs commonly manipulate physicians 
into prescribing higher doses or stronger types of opioids than 
are needed to achieve pain relief and control.3 Thus, there 
is a critical need to advocate for the extension of existing   Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
104
Francoeur
community residential drug treatment programs, MMTP 
clinics, medical outpatient clinics, visiting nurse services, and 
social work consultation – in order to conduct mandatory pill 
counting (which may involve use of a pill-counting machine), 
urine analyses, and psychosocial monitoring during home 
and/or agency visits – when patients receiving controlled 
substance medications have a personal or family history of 
drug abuse or diversion activities. These programs/settings 
should be included as part of the patient contract with their 
physician. Facilitating timely communication between the 
palliative care team and the interdisciplinary teams from these 
settings should become a priority.
Moreover, the scope for program linkage with existing 
community services may be wider than anticipated since there 
is precedence for nonmedical providers to engage in pill count-
ing and psychosocial monitoring. Social service providers, 
for instance, already 1) oversee individuals with co-occurring 
mental health/mental retardation conditions who live together 
in a community residence, as they take medications for psy-
chiatric and medical conditions (usually twice a day); and 
2) conduct pill counts for these individuals on a daily basis.
Patients with reduced access to care are also more likely to 
delay treatment for pain. Respected and well established social 
networks in some communities, such as religious networks of 
clergy and church members, may be trusted by community 
residents when they need help accessing medical care.16 By 
conducting outreach and planning with these networks, pal-
liative clinicians may anticipate   “snowball” effects of new 
referrals of residents. Social workers, clergy, church members, 
and neighborhood leaders might consider how those who are 
uninsured, underinsured, or indigent, may be referred earlier in 
the disease course, when there may be more options for achiev-
ing and maintaining control over pain and symptoms.16
Conclusions
Societal expectations are likely to evolve for clinicians from 
retail and hospital pharmacies, pharmacy clinics, interdisci-
plinary health care teams, community drug-treatment pro-
grams, and social service agencies to assess and minimize 
the risks in meeting the twin goals of ensuring safe and 
affordable access to medications for palliative care while 
preventing prescription drug abuse and diversion. This article 
has presented a vision of geographic and service delivery 
innovations that begin to meet these competing bioethical 
goals. It is important to recognize that safe medication dis-
pensing centers located within retail pharmacies or pharmacy 
clinics would operate as the centralized program component 
for hosting or coordinating most of the other interventions. 
Pharmacists at safe medication dispensing centers would 
work with assigned or off-duty police officer guards at these 
centers to plan and oversee the safe storage of controlled 
substance medications in off-site community safe-deposit 
boxes. These pharmacists would also work with other profes-
sionals in the community – such as medical providers, social 
workers, hospital administrators and reimbursement officers, 
and drug abuse counselors – to: strengthen communication 
and cooperation with the prescribing medical provider; assist 
the prescribing medical provider in patient monitoring (ie, 
review the state prescription registry for evidence of doctor or 
pharmacy shopping; provide pill counts and urine samples); 
expand access to lower-cost formulations, and in some cases, 
TARD formulations  of   controlled substance medications; 
improve transportation access for underserved patients and 
caregivers to obtain prescriptions; and integrate community 
agencies and social networks as resources for patient support 
and   monitoring. A couple of community program compo-
nents may be hosted outside safe medication dispensing 
centers – developing medication purchasing cooperatives and 
expanding the role of inner-city MMTPs in palliative care. 
Increasingly, pharmacists, police, physicians, other medical 
providers, social workers, other mental health/drug abuse 
clinicians, and hospital administrators should work together 
as community leaders in this new area.
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